A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
This study is enrolling participants by invitation only.
Study NCT00851890.
Last updated on April 29, 2009.
Information provided by Abbott
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
